{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:45:07Z","timestamp":1792320307813,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s11523-023-01026-9","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T11:43:09Z","timestamp":1705578189000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"19","author":[{"given":"Nicole L.","family":"France","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"issue":"6","key":"1026_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606.","journal-title":"J Hepatol"},{"key":"1026_CR2","unstructured":"Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma [updated 2023 June 12] In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan-. 2023. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32644603. Accessed 5 Dec 2023."},{"issue":"2","key":"1026_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","volume":"69","author":"GM Keating","year":"2009","unstructured":"Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223\u201340.","journal-title":"Drugs"},{"key":"1026_CR4","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Hepatocellular carcinoma version 2. 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hcc.pdf. Accessed 5 Dec 2023."},{"issue":"9","key":"1026_CR5","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386.","journal-title":"Cancer Discov"},{"issue":"1","key":"1026_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98\u2013106.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"1026_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"3","key":"1026_CR8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","volume":"162","author":"GL Su","year":"2022","unstructured":"Su GL, Altayar O, O\u2019Shea R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162(3):920\u201334.","journal-title":"Gastroenterology"},{"issue":"4","key":"1026_CR9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","volume":"75","author":"J Bruix","year":"2021","unstructured":"Bruix J, Chan SL, Galle PR, et al. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75(4):960\u201374.","journal-title":"J Hepatol"},{"issue":"6","key":"1026_CR10","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u201365.","journal-title":"Hepatology"},{"issue":"8","key":"1026_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):1\u201312.","journal-title":"NEJM Evid."},{"issue":"2","key":"1026_CR12","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79(2):506\u201315.","journal-title":"J Hepatol"},{"issue":"1","key":"1026_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77\u201390.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1026_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40265-022-01827-8","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Tremelimumab: first approval. Drugs. 2023;83(1):93\u2013102.","journal-title":"Drugs"},{"key":"1026_CR15","unstructured":"AstraZeneca Pharmaceuticals LP. Imjudo - tremelimumab injection, solution: US prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761289. Accessed 5 Dec 2023."},{"key":"1026_CR16","unstructured":"AstraZeneca. Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers. 2022. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/imfinzi-imjudo-approved-in-japan-for-3-cancers.html. Accessed 5 Dec 2023."},{"key":"1026_CR17","unstructured":"AstraZeneca AB. Imjudo: summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imjudo#product-information-section. Accessed 5 Dec 2023."},{"issue":"7_Suppl","key":"1026_CR18","first-page":"877","volume":"64","author":"DC Hanson","year":"2004","unstructured":"Hanson DC, Canniff PC, Primiano MJ, et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. [abstract no. 3802]. Cancer Res. 2004;64(7_Suppl):877.","journal-title":"Cancer Res"},{"key":"1026_CR19","unstructured":"Center for Drug Evaluation and Research (CDER). Tremelimumab (Imjudo) multi-discipline review. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761289Orig1s000MultidisciplineR.pdf. Accessed 5 Dec 2023."},{"issue":"27","key":"1026_CR20","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","volume":"39","author":"RK Kelley","year":"2021","unstructured":"Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study. J Clin Oncol. 2021;39(27):2991\u20133001.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1026_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1158\/1078-0432.CCR-22-1983","volume":"29","author":"X Song","year":"2023","unstructured":"Song X, Kelley RK, Khan AA, et al. Exposure-response analyses of tremelimumab monotherapy or in combination with durvalumab in patients with unresectable hepatocellular carcinoma. Clin Cancer Res. 2023;29(4):754\u201363.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1026_CR22","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/jcph.2288","volume":"63","author":"K Lim","year":"2023","unstructured":"Lim K, Abegesah A, Fan C, et al. Population pharmacokinetics and exposure-response analysis of tremelimumab 300 mg single dose combined with durvalumab 1500 mg Q4W (STRIDE) in patients with unresectable hepatocellular carcinoma. J Clin Pharmacol. 2023;63(11):1221\u201331.","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"1026_CR23","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1016\/j.annonc.2023.04.487","volume":"34","author":"B Sangro","year":"2023","unstructured":"Sangro B, Chan S, Kelley R, et al. Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma [abstract no. SO-15 plus presentation]. Ann Oncol. 2023;34(Suppl 1):S168.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"1026_CR24","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/S0168-8278(22)00607-9","volume":"77","author":"L Qin","year":"2022","unstructured":"Qin L, Miranda M, Shephard C, et al. The impact of treatment and treatment status on health state utility in patients with unresectable hepatocellular carcinoma: an EQ-5D analysis from Himalaya [abstract no. OS161]. J Hepatol. 2022;77(Suppl 1):S110.","journal-title":"J Hepatol"},{"key":"1026_CR25","doi-asserted-by":"crossref","unstructured":"Lau G, Sangro B, Crysler OV, et al. Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) [abstract no. 4073]. J Clin Oncol. 2023;41(16_Suppl).","DOI":"10.1200\/JCO.2023.41.16_suppl.4073"},{"issue":"16_Suppl","key":"1026_CR26","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.2023.41.16_suppl.4004","volume":"41","author":"G Lau","year":"2023","unstructured":"Lau G, Cheng A-L, Sangro B, et al. Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) [abstract no. 4004]. J Clin Oncol. 2023;41(16_Suppl).","journal-title":"J Clin Oncol"},{"issue":"20","key":"1026_CR27","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1026_CR28","unstructured":"Greten TF, Abou-Alfa G, Cheng A, et al. Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2023. doi.org\/10.1136\/jitc-2021-002794add1."},{"key":"1026_CR29","unstructured":"European Medicines Agency (EMA). EMA recommends extenstion of indications for durvalumab in the management of HCC. 2023. https:\/\/www.esmo.org\/oncology-news\/. Accessed 5 Dec 2023."},{"issue":"5","key":"1026_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","volume":"53","author":"K Hasegawa","year":"2023","unstructured":"Hasegawa K, Takemura N, Yamashita T, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2021 version (5th JSH-HCC guidelines). Hepatol Res. 2023;53(5):383\u201390.","journal-title":"Hepatol Res"},{"key":"1026_CR31","unstructured":"European Medicines Agency (EMA). ESMO-MCBS Scorecards. Tremelimumb. Himalaya. 2023. https:\/\/www.esmo.org\/guidelines\/. Accessed 5 Dec 2023."},{"key":"1026_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2022.06.058","volume":"174","author":"CAM Fulgenzi","year":"2022","unstructured":"Fulgenzi CAM, D\u2019Alessio A, Airoldi C, et al. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials. Eur J Cancer. 2022;174:57\u201367.","journal-title":"Eur J Cancer"},{"key":"1026_CR33","doi-asserted-by":"crossref","unstructured":"Qin L, Chan S, Le Nouveau P, et al. Matching adjusted indirect comparison (MAIC) of single tremelimumab regular interval durvalumab (STRIDE) versus atezolizumab with bevacizumab (A+B) for the treatment of unresectable hepatocellular carcinoma (UHCC) [abstract no. CO70]. Value Health. 2023;26(6 Suppl. 2):S27.","DOI":"10.1016\/j.jval.2023.03.144"},{"issue":"6","key":"1026_CR34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.21037\/hbsn-22-510","volume":"11","author":"T Hatanaka","year":"2022","unstructured":"Hatanaka T, Naganuma A, Yata Y, et al. Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? Hepatobiliary Surg Nutr. 2022;11(6):927\u201330.","journal-title":"Hepatobiliary Surg Nutr."}],"updated-by":[{"DOI":"10.1007\/s11523-024-01053-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000}}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-01026-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T07:13:41Z","timestamp":1711005221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-01026-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1026"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-01026-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"5 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11523-024-01053-0","URL":"https:\/\/doi.org\/10.1007\/s11523-024-01053-0","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nicole L. France and Hannah A. Blair are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}